AMLX vs SRE · $561.6M cap vs P/E 31, rev $13.70B
Amylyx Pharmaceuticals Inc (AMLX) versus Sempra Energy (SRE) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Sempra Energy (SRE) is a utilities - diversified company listed on US.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
Latest reported SRE revenue for 2025-12-31 was $13.70B. Net income was $1.84B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
AMLX currently screens at market cap $561.6M. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
Not investment advice. Open the AMLX and SRE stock pages for the full models.
Not investment advice.